Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161356 · ClinicalTrials.gov registry record · Phase 4
Ambisome in Liver Transplant Patients
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00161356 is a Phase 4 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 10 participants.
The verdict
NCT00161356, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body. This drug is approved for treatment of infections caused by fungus and is known to be effective against most of the fungal infections, which can happen after liver transplantation. By taking small pieces (less than quarter of a teaspoon) of liver and fat during the liver transplant operation, we can measure how much of the drug is concentrated in the liver. After that, we will measure the level of the drug in the blood and in the bile that comes out of a small tube which is inserted into the bile tube as a routine in all liver transplant patients. These measurements will be taken daily for a week and then weekly for another 3 weeks. We are inviting you to take part in this study in order to increase our knowledge of the behavior of this drug so that we can find the most effective treatment to prevent fungal infections in liver transplant patients.
Interventions
- PROCEDURE Liver Biopsy
- DRUG Ambisome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161356
The ClinicalTrials.gov registry entry for NCT00161356 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liver Biopsy is the first listed.
NCT00161356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00161356 about?
NCT00161356 is a clinical study titled "Ambisome in Liver Transplant Patients". In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body. This drug is approved for treatment of infections caused by fungus and is known to be effective against most of the fungal infections, which can happen af...
What is the current status of trial NCT00161356?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2005-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00161356?
The interventions under investigation include: Liver Biopsy (PROCEDURE), Ambisome (DRUG).
Who is sponsoring clinical trial NCT00161356?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.